GB0701992D0 - Grehlin Receptor Modulators - Google Patents

Grehlin Receptor Modulators

Info

Publication number
GB0701992D0
GB0701992D0 GBGB0701992.0A GB0701992A GB0701992D0 GB 0701992 D0 GB0701992 D0 GB 0701992D0 GB 0701992 A GB0701992 A GB 0701992A GB 0701992 D0 GB0701992 D0 GB 0701992D0
Authority
GB
United Kingdom
Prior art keywords
grehlin
receptor modulators
modulators
receptor
grehlin receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0701992.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
7TM Pharma AS
Original Assignee
7TM Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 7TM Pharma AS filed Critical 7TM Pharma AS
Priority to GBGB0701992.0A priority Critical patent/GB0701992D0/en
Publication of GB0701992D0 publication Critical patent/GB0701992D0/en
Priority to PCT/EP2008/000758 priority patent/WO2008092681A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0701992.0A 2007-02-02 2007-02-02 Grehlin Receptor Modulators Ceased GB0701992D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0701992.0A GB0701992D0 (en) 2007-02-02 2007-02-02 Grehlin Receptor Modulators
PCT/EP2008/000758 WO2008092681A1 (fr) 2007-02-02 2008-01-29 Modulateurs du récepteur de la ghréline

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0701992.0A GB0701992D0 (en) 2007-02-02 2007-02-02 Grehlin Receptor Modulators

Publications (1)

Publication Number Publication Date
GB0701992D0 true GB0701992D0 (en) 2007-03-14

Family

ID=37891166

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0701992.0A Ceased GB0701992D0 (en) 2007-02-02 2007-02-02 Grehlin Receptor Modulators

Country Status (2)

Country Link
GB (1) GB0701992D0 (fr)
WO (1) WO2008092681A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586619B2 (en) 2007-03-12 2013-11-19 Vm Therapeutics Llc Agents of calcium ion channel modulators
DK3092901T3 (da) 2007-10-05 2020-05-18 Senhwa Biosciences Inc Quinolonanaloger og fremgangsmåder relateret dertil
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
WO2012113103A1 (fr) 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Urées asymétriques et leurs utilisations médicales
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
CN105085278A (zh) * 2015-08-07 2015-11-25 常州大学 一种2-甲基-1-取代苯基-2-丙胺类化合物的制备方法
WO2017087235A1 (fr) 2015-11-20 2017-05-26 Senhwa Biosciences, Inc. Polythérapie comprenant des analogues de la quinolone tétracyclique pour le traitement du cancer
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
EA037040B1 (ru) 2016-03-22 2021-01-29 Хелсинн Хелскеа Са Асимметричные бензолсульфонилмочевины и их применение в качестве модуляторов рецептора грелина
WO2019168688A2 (fr) 2018-02-15 2019-09-06 Senhwa Biosciences, Inc. Analogues de quinolone, sels correspondants, compositions et procédé d'utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0515684A4 (en) * 1990-02-14 1993-04-21 Chugai Seiyaku Kabushiki Kaisha Inhibitor of denatured ldl formation

Also Published As

Publication number Publication date
WO2008092681A1 (fr) 2008-08-07

Similar Documents

Publication Publication Date Title
HK1259082A1 (zh) 大麻素受體調節劑
EP2179061A4 (fr) Modulateurs de récepteur de type péage
IL208185A0 (en) Chemokine receptor modulators
GB0701992D0 (en) Grehlin Receptor Modulators
IL198990A0 (en) Cb1 receptor modulators
SI2297100T1 (sl) Tetrahidrociklopenta(b)indoli kot modulatorji androgenskega receptorja
IL204786A0 (en) Benzyl - cycloalkyl sphingosing 1 - phosphate receptor modulators
GB2462235B8 (en) Receptor modulators exhibiting neuroprotective andmemory enhancing activities
ZA201004828B (en) Cannabinoid receptor modulators
ZA201002268B (en) Benzothiazoles as ghrelin receptor modulators
HRP20130409T1 (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators
EP2303275A4 (fr) Modulateurs du récepteur smoothened
EP2139489A4 (fr) Modulateurs des récepteurs de minéralocorticoïdes
GB0622569D0 (en) Cannabinoid receptor modulators
EP2229167A4 (fr) Modulateurs des récepteurs minéralocorticoïdes
ZA200806237B (en) Cannibinoid receptor modulators
HK1126767A1 (en) Pyridooxazepine progesteron receptor modulators
GB0811212D0 (en) CB1 Receptor Modulators
EP2288612A4 (fr) Modulateurs des récepteurs gabaa
ZA200907546B (en) New progesterone receptor modulators
ZA200904663B (en) CB1 receptor modulators
GB0717998D0 (en) Canabinoid receptor modulators
GB0724096D0 (en) Cannabinoid receptor modulators
GB0813350D0 (en) Cannabinoid receptor modulators
GB0807710D0 (en) Receptor and modulators thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)